We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: heart failure
MedXY News
EnglishTag

heart failure

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersclinical trialsartificial intelligenceHypertensionCardiologyoncologytype 1 diabetespublic healthMortalitydiabetesAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Biventricular Pacing Outperforms Conduction System Pacing in Heart Failure: Key Insights from PhysioSync-HF Trial
CardiologyBiventricular pacingconduction system pacing

Biventricular Pacing Outperforms Conduction System Pacing in Heart Failure: Key Insights from PhysioSync-HF Trial

By MedXY|Apr 22, 2026

PhysioSync-HF trial reveals CSP is inferior to BiVP for HFrEF patients with LBBB, challenging its role as a first-line resynchronization therapy despite cost benefits.

LBBP Outperforms BiVP: 74% Reduction in Death or Heart Failure Hospitalization at 3 Years
CardiologyBiventricular pacingheart failure

LBBP Outperforms BiVP: 74% Reduction in Death or Heart Failure Hospitalization at 3 Years

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
By MedXY|Apr 18, 2026

The HeartSync-LBBP trial reveals left bundle-branch pacing reduces the composite of death or heart failure hospitalization by 74% compared to biventricular pacing, with significantly higher super-response rates in patients with reduced ejec

Persistent Fibroblast Activation Predicts Heart Failure Progression: [68Ga]FAPI-46 PET/MRI Reveals Distinct Patterns in Ischemic and Nonischemic Cardiomyopathy
Cardiologycardiac imagingFAPI PET

Persistent Fibroblast Activation Predicts Heart Failure Progression: [68Ga]FAPI-46 PET/MRI Reveals Distinct Patterns in Ischemic and Nonischemic Cardiomyopathy

By MedXY|Apr 15, 2026

A prospective case-control study demonstrates that myocardial fibroblast activation persists in heart failure patients and follows distinct spatial patterns depending on etiology. Using [68Ga]FAPI-46 PET/MRI, researchers found that higher b

Exercise Unmasks Multi-Organ Deficits That Predict Heart Failure Risk: Metabolite Signatures Reveal Shared Pathways Across HFpEF and Its Comorbidities
Cardiologycardiopulmonary exercise testingheart failure

Exercise Unmasks Multi-Organ Deficits That Predict Heart Failure Risk: Metabolite Signatures Reveal Shared Pathways Across HFpEF and Its Comorbidities

By MedXY|Apr 15, 2026

A landmark study reveals that exercise-induced multi-organ physiologic deficits strongly predict incident heart failure with preserved ejection fraction (HFpEF). Using invasive cardiopulmonary testing, metabolomics, and genomics across over

LBBP Matches BiVP in ECG Metrics but Excels at Cellular Level: Canine Study Redefines Cardiac Resynchronization Therapy
CardiologyBiventricular pacingCanine model

LBBP Matches BiVP in ECG Metrics but Excels at Cellular Level: Canine Study Redefines Cardiac Resynchronization Therapy

By MedXY|Apr 6, 2026

A canine study reveals left bundle branch pacing achieves equivalent QRS narrowing and ejection fraction improvement as biventricular pacing, yet demonstrates superior recovery of cardiac mechanics, calcium handling, and energy metabolism a

Decoding the Heart Failure Peptidome: A Cross-Sectional Study Uncovers Novel Biomarkers and Patient Clusters
Cardiologybiomarkersheart failure

Decoding the Heart Failure Peptidome: A Cross-Sectional Study Uncovers Novel Biomarkers and Patient Clusters

By MedXY|Apr 5, 2026

A groundbreaking mass spectrometry study analyzing 486 heart failure patients and 98 controls identified over 21,000 unique peptides, revealing 1,924 differentially expressed peptides. The research highlights angiotensin-related peptides, n

Only 1 in 5 Veterans with Heart Failure Achieve Recommended Quadruple Therapy Within 3 Years—What This Means for Clinical Practice
CardiologyGDMThealth equity

Only 1 in 5 Veterans with Heart Failure Achieve Recommended Quadruple Therapy Within 3 Years—What This Means for Clinical Practice

By MedXY|Apr 5, 2026

A large retrospective study of 52,850 veterans reveals that just 21.2% achieve guideline-directed quadruple therapy for HFrEF, with a median time of 197 days. Socioeconomic barriers, including prescription copays, emerge as critical modifia

Mid-Regional Pro-Adrenomedullin (MR-proADM): A Superior Prognostic Sentinel in Transthyretin Cardiac Amyloidosis
CardiologyAmyloidosisATTR-CM

Mid-Regional Pro-Adrenomedullin (MR-proADM): A Superior Prognostic Sentinel in Transthyretin Cardiac Amyloidosis

By MedXY|Apr 2, 2026

This review synthesizes recent evidence identifying MR-proADM as a premier prognostic biomarker in ATTR-CM, demonstrating its ability to outperform traditional natriuretic peptides and enhance existing clinical staging systems.

TEER vs. Medical Therapy: Redefining the Management of Atrial Functional Mitral Regurgitation
CardiologyAFMRheart failure

TEER vs. Medical Therapy: Redefining the Management of Atrial Functional Mitral Regurgitation

By MedXY|Mar 27, 2026

A large-scale registry analysis demonstrates that Transcatheter Edge-to-Edge Repair (TEER) significantly reduces mortality and heart failure hospitalizations in patients with atrial functional mitral regurgitation (AFMR) compared to medical

Decoding the Diabetic Heart: Five Unique Proteomic Markers Unveil Heart Failure Risk in Patients with Diabetes
CardiologybiomarkersDiabetes Mellitus

Decoding the Diabetic Heart: Five Unique Proteomic Markers Unveil Heart Failure Risk in Patients with Diabetes

By MedXY|Mar 26, 2026

Researchers from the ARIC study have identified five specific proteomic markers that uniquely predict heart failure risk in individuals with diabetes. These findings, including four novel proteins, suggest distinct pathophysiological pathwa

Navigating the AfMR Maze: Expert Consensus and the Future of Mitral Regurgitation Diagnosis
CardiologyCardiologyESC Guidelines

Navigating the AfMR Maze: Expert Consensus and the Future of Mitral Regurgitation Diagnosis

By MedXY|Mar 25, 2026

This article examines the debate between JACC and ESC definitions for Atrial Functional Mitral Regurgitation (AfMR), highlighting why the JACC Expert Consensus offers a more robust framework for clinical prognosis and patient classification

Decoding the Diabetic Heart: Novel Proteomic Signatures of Heart Failure Risk in the ARIC Study
CardiologyARIC Studybiomarkers

Decoding the Diabetic Heart: Novel Proteomic Signatures of Heart Failure Risk in the ARIC Study

By MedXY|Mar 22, 2026

A comprehensive review of the ARIC study’s identification of five unique proteomic markers—four novel—that specifically predict heart failure risk in patients with diabetes, offering new insights into lipid metabolism and inflammatory

Redefining Risk in Diabetic Kidney Disease: The 2022 AHA/ACC/HFSA Heart Failure Staging and the Efficacy of Sotagliflozin
Clinical UpdatesAHA/ACC/HFSA StagingBệnh Thận Do Tiểu Đường

Redefining Risk in Diabetic Kidney Disease: The 2022 AHA/ACC/HFSA Heart Failure Staging and the Efficacy of Sotagliflozin

By MedXY|Mar 20, 2026

This review analyzes the prognostic value of the 2022 Heart Failure staging in patients with diabetes and kidney disease, highlighting the high risk of asymptomatic ‘Pre-HF’ and the consistent therapeutic benefits of sotaglifloz

Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis
CardiologyCardiologyendomyocardial biopsy

Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis

By MedXY|Mar 20, 2026

This article explores a major international study of 156 acute eosinophilic myocarditis patients, revealing high mortality rates, the diagnostic necessity of endomyocardial biopsy, and the critical survival benefit of early immunosuppressiv

Rethinking Mitral Regurgitation in Hypertrophic Cardiomyopathy: Lessons from the REVEAL-HCM Study
Cardiologyheart failureHypertrophic Cardiomyopathy

Rethinking Mitral Regurgitation in Hypertrophic Cardiomyopathy: Lessons from the REVEAL-HCM Study

By MedXY|Mar 20, 2026

The REVEAL-HCM study demonstrates that the prognostic impact of mitral regurgitation varies significantly across HCM subtypes, with notable risk in nonobstructive and apical forms, but not in obstructive or end-stage HCM.

Ethnic Minority Patients with Heart Failure in England Achieve Superior Survival: The Crucial Role of Specialist Care and Medication Adherence
CardiologyCardiologyclinical outcomes

Ethnic Minority Patients with Heart Failure in England Achieve Superior Survival: The Crucial Role of Specialist Care and Medication Adherence

By MedXY|Mar 20, 2026

A large-scale analysis of 239,890 patients in England reveals that Black, Asian, and mixed-ethnicity patients hospitalized for heart failure have significantly lower mortality rates than White patients, largely due to better pharmacological

Transcatheter Edge-to-Edge Repair Superior to Medical Therapy in Atrial Functional Mitral Regurgitation: Evidence from Real-World Registries
CardiologyAFMRCardiology

Transcatheter Edge-to-Edge Repair Superior to Medical Therapy in Atrial Functional Mitral Regurgitation: Evidence from Real-World Registries

By MedXY|Mar 17, 2026

A propensity score-based study demonstrates that transcatheter edge-to-edge repair (TEER) significantly reduces mortality and heart failure hospitalizations in patients with atrial functional mitral regurgitation compared to medical therapy

CRLF1 Secreted by Cardiac Fibroblasts: A New Driver and Potential Therapeutic Target for Hypertrophic Cardiomyopathy
CardiologyCardiac FibroblastsCRLF1

CRLF1 Secreted by Cardiac Fibroblasts: A New Driver and Potential Therapeutic Target for Hypertrophic Cardiomyopathy

By MedXY|Mar 17, 2026

This article explores a groundbreaking study identifying CRLF1, a protein secreted by cardiac fibroblasts, as a key driver of Hypertrophic Cardiomyopathy (HCM). This paracrine signaling mechanism offers a potential universal therapeutic tar

Interaction Between SGLT2 Inhibition and Dietary Sodium: Insights from the CREDENCE Trial Post Hoc Analysis
CardiologyCanagliflozinchronic kidney disease

Interaction Between SGLT2 Inhibition and Dietary Sodium: Insights from the CREDENCE Trial Post Hoc Analysis

By MedXY|Mar 15, 2026

This post hoc analysis of the CREDENCE trial reveals that low-normal sodium intake increases cardiovascular risk in T2D and CKD, a risk significantly mitigated by canagliflozin, while renal protection remains consistent across sodium intake

Optimized Heart Failure Therapy in Advanced Cancer: Insights from the EMPATICC Trial
CardiologyCardio-Oncologyclinical trials

Optimized Heart Failure Therapy in Advanced Cancer: Insights from the EMPATICC Trial

By MedXY|Mar 12, 2026

The EMPATICC trial explored heart failure therapy for patients with advanced cancer in palliative care. While it did not meet its primary endpoint for self-care ability due to high mortality, survivors showed improved cardiac biomarkers and

Prev
4 / 10
123456…10
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure